Plasma p-tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease

dc.contributor.authorAguillon, David
dc.contributor.authorLangella, Stephanie
dc.contributor.authorChen, Yinghua
dc.contributor.authorSanchez, Justin
dc.contributor.authorSu, Yi
dc.contributor.authorVila-Castelar, Clara
dc.contributor.authorVasquez, Daniel
dc.contributor.authorZetterberg, Henrik
dc.contributor.authorHansson, Oskar
dc.contributor.authorDage, Jeffrey L.
dc.contributor.authorJanelidze, Shorena
dc.contributor.authorChen, Kewei
dc.contributor.authorFox-Fuller, Joshua T.
dc.contributor.authorAduen, Paula
dc.contributor.authorMartinez, Jairo E.
dc.contributor.authorGarcia, Gloria
dc.contributor.authorBaena, Ana
dc.contributor.authorGuzman, Claudia
dc.contributor.authorJohnson, Keith
dc.contributor.authorSperling, Reisa A.
dc.contributor.authorBlennow, Kaj
dc.contributor.authorReiman, Eric M.
dc.contributor.authorLopera, Francisco
dc.contributor.authorQuiroz, Yakeel T.
dc.contributor.departmentNeurology, School of Medicine
dc.date.accessioned2024-09-09T12:24:15Z
dc.date.available2024-09-09T12:24:15Z
dc.date.issued2023
dc.description.abstractIntroduction: Plasma-measured tau phosphorylated at threonine 217 (p-tau217) is a potential non-invasive biomarker of Alzheimer's disease (AD). We investigated whether plasma p-tau217 predicts subsequent cognition and positron emission tomography (PET) markers of pathology in autosomal dominant AD. Methods: We analyzed baseline levels of plasma p-tau217 and its associations with amyloid PET, tau PET, and word list delayed recall measured 7.61 years later in non-demented age- and education-matched presenilin-1 E280A carriers (n = 24) and non-carrier (n = 20) family members. Results: Carriers had higher plasma p-tau217 levels than non-carriers. Baseline plasma p-tau217 was associated with subsequent amyloid and tau PET pathology levels and cognitive function. Discussion: Our findings suggest that plasma p-tau217 predicts subsequent brain pathological burden and memory performance in presenilin-1 E280A carriers. These results provide support for plasma p-tau217 as a minimally invasive diagnostic and prognostic biomarker for AD, with potential utility in clinical practice and trials. Highlights: Non-demented presenilin-1 E280A carriers have higher plasma tau phosphorylated at threonine 217 (p-tau217) than do age-matched non-carriers. Higher baseline p-tau217 is associated with greater future amyloid positron emission tomography (PET) pathology burden. Higher baseline p-tau217 is associated with greater future tau PET pathology burden. Higher baseline p-tau217 is associated with worse future memory performance.
dc.eprint.versionAuthor's manuscript
dc.identifier.citationAguillon D, Langella S, Chen Y, et al. Plasma p-tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease. Alzheimers Dement. 2023;19(6):2585-2594. doi:10.1002/alz.12906
dc.identifier.urihttps://hdl.handle.net/1805/43205
dc.language.isoen_US
dc.publisherWiley
dc.relation.isversionof10.1002/alz.12906
dc.relation.journalAlzheimer's & Dementia
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectAutosomal dominant Alzheimer's disease
dc.subjectBlood biomarkers
dc.subjectDementia
dc.subjectPresenilin-1
dc.subjectTau pathology
dc.titlePlasma p-tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Aguillon2023Plasma-AAM.pdf
Size:
1.28 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: